Navigation Links
Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation

SEATTLE, Aug. 29 /PRNewswire/ -- Attorneys representing consumers in a case accusing McKesson (NYSE: MCK) of illegally rigging the price of virtually every prescription drug have crossed the final procedural hurdles and are now preparing for a trial set for December 1 in U.S. District Court in Boston.


Attorney Steve W. Berman filed the suit in 2006 on behalf of third-party payers and consumers, claiming that McKesson engaged in a scheme to fraudulently inflate the price of more than 400 prescription drugs, including blockbusters such as Prozac, Lipitor, Zocor, Vioxx and more.

On March 18, 2008, Judge Patti Saris for a second time rejected McKesson's motions to dismiss the case, citing the strength of the evidence, which includes volumes of e-mail exchanges by McKesson executives discussing the price-fixing scheme. The plaintiffs in the case peg the damages at $4 billion, which puts McKesson at risk of a $12 billion judgment with the tripling of damages allowed by the RICO statute under which the suits were filed.

RICO -- the Racketeer Influenced and Corrupt Organizations Act -- allows for civil action against those believed to participate in conspiracies to commit crimes or illegally reap profits. The law calls for the disgorgement of ill-gotten profits and the tripling of damages.

Judge Patti Saris earlier this week dismissed a related case charging the drug giant of antitrust violations.

"We believe the antitrust laws were intended to address the sort of disingenuous behavior McKesson exhibited, but we recognize that the allegations presented a context not directly addressed by prior case-law," Berman said. "We understand and appreciate Judge Saris' ruling, and are eager to move forward with the strongest case -- the RICO charges."

The case represents two classes: consumer purchasers, which includes anyone who made a co-payment for prescription medication from August 1, 2001 through May 15, 2005, and all third-party payers that made a payment or reimbursement based on the inflated average wholesale price (AWP) during the class period.

The suit claims McKesson and First DataBank, a publishing company, reached a secret agreement on how the average wholesale price would be set for brand-name drugs and, in doing so, raised the spread between the published AWP and the actual acquisition costs from 20 to 25 percent in an effort to increase profits.

Earlier this year, First DataBank settled with plaintiffs, leaving McKesson as the sole defendant.

According to documents cited in the case, McKesson communicated the price increase to First DataBank, who published the information, even amid questions by manufacturers who recognized the impact to consumers and third-party payers. McKesson did so to raise the profits for its large clients like Rite Aid and Walgreen's.

For more information on this case and to sign up as a consumer or third-party payer you can visit the Hagens Berman Web site at

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro, is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix, San Francisco and New York. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation, one of the largest anti-trust settlements in history; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit


Steve Berman (206) 623-7292 Mark Firmani (206) 919-9357

Hagens Berman Sobol Shapiro Firmani + Associates Inc.

SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
2. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
3. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
4. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
5. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
6. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
7. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
8. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
9. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
10. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
11. Social Security Attorneys Prepare for Increased Baby Boomer SSI Claims
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging ... owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating ... North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... Lutronic, a leading innovator of aesthetic and medical laser ... devices for sale in the United States. Clarity is a Superior Dual Wavelength ... lasers, into a single platform that is easy to own and operate. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of ... SACC-USA . Gary has spent a significant amount of time in Sweden since ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and TELTOW, Germany , December 1, ... , a leading global manufacturer of eye and gaze ... has included SMI remote eye trackers as a component ... providers assess concussions, eye sight, and medical and performance ... technology is part of SMI,s mass-market-ready eye tracking platform, ...
(Date:12/1/2015)... Dec. 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast ... --> ) has announced the addition ... - Forecast to 2020" report to their ... ) has announced the addition of the ...
(Date:12/1/2015)... Calif. , Dec. 1, 2015  Avanir ... prevalence of symptoms for pseudobulbar affect (PBA), a ... of laughing and/or crying resulting from certain neurologic ... of antipsychotic medications in nursing home residents, were ... Psychiatry. The study showed that almost one in ...
Breaking Medicine Technology: